Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is conducting a Phase 3b/4 clinical study ...

Atopic dermatitis (the most common type of eczema) causes dry, itchy skin with rough, scaly patches. It affects up to 30% of children and 10% of adults, with about 60% of cases starting before age 1.

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that significantly impacts quality of life and often ...

EP: 12. EP: 13. EP: 14. Casey Butrus, PharmD: Dr Keegan, explain the treatment landscape for atopic dermatitis [AD] and the therapeutic categories and options we have available for our patients.

Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

"The study adds to growing evidence that dupilumab, while highly effective for managing atopic dermatitis, may also be linked ...

Atopic dermatitis, the most common form of eczema, is a widespread skin condition known for causing dry, itchy and inflamed skin. It affects 15% to 20% of children and 8% to 10% of adults.

Patients with moderate to severe atopic dermatitis treated with amlitelimab showed both clinical and biomarker improvements, including in patients who withdrew from treatment, according to phase ...

Dupilumab, an anti-IL-4 and anti-IL-13 monoclonal antibody, is indicated in Europe for the treatment of moderate to severe atopic dermatitis that requires systemic treatment.

Biologics for the Treatment of Adolescent Atopic Dermatitis : Episode 5 Video May 29, 2019 ...

The use of topical corticosteroids to treat atopic dermatitis in infants also may help prevent hen’s egg allergy, but it may inhibit the baby’s growth as well, according to a study published ...

University of Zurich. "New potential approach to treat atopic dermatitis." ScienceDaily. ScienceDaily, 18 March 2019. <www.sciencedaily.com / releases / 2019 / 03 / 190318111958.htm>.